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Abstract 
Background: The heritability of opioid use disorder has been widely investigated; however, the influence of specific 
genes on methadone treatment outcomes is not well understood. The association between response to methadone 
treatment and genes that are involved in substance use behaviors and reward mechanisms is poorly understood, 
despite evidence suggesting their contribution to opioid use disorder. The aim of this study was to investigate the 
effect of brain-derived neurotrophic factor (BDNF) and dopamine receptor D2 (DRD2) polymorphisms on continued 
opioid use among patients on methadone treatment for opioid use disorder.
Methods: BDNF 196G>A (rs6265) and DRD2-241A>G (rs1799978) genetic variants were examined in patients with 
opioid use disorder who were recruited from methadone treatment clinics across Southern Ontario, Canada. We col-
lected demographic information, substance use history, blood for genetic analysis, and urine to measure opioid use. 
We used regression analysis to examine the association between continued opioid use and genetic variants, adjusting 
for age, sex, ethnicity, methadone dose, duration in treatment, and number of urine screens.
Results: Among 240 patients treated with methadone for opioid use disorder, 36.3 percent (n = 87) and 11.3 percent 
(n = 27) had at least one risk allele for rs6265 and rs1799978, respectively. These genetic variants were not significantly 
associated with continued opioid use while on methadone maintenance treatment [rs6265: odds ratio (OR) = 1.37, 
95 % confidence interval (CI) = 0.792, 2.371, p = 0.264; rs1799978: OR 1.27, 95 % CI 0.511, 3.182, p = 0.603].
Conclusions: Despite an association of BDNF rs6265 and DRD2 rs1799978 with addictive behaviors, these variants 
were not associated with continued illicit opioid use in patients treated with methadone. Problematic use of opioids 
throughout treatment with methadone may be attributed to nongenetic factors or a polygenic effect requiring 
further exploration. Additional research should focus on investigating these findings in larger samples and different 
populations.
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Background
Rates of illicit opioid use are continuing to rise on a global 
scale, with North America being among the regions with 
most problematic levels of opioid use [1, 2]. Now identi-
fied as a growing public health problem, the use of illicit 
opioids is putting individuals at risk for opioid-related 
problems, including psychological and physical depend-
ence. The development of opioid use disorder is influ-
enced by a combination of environmental, behavioral, 
and biological factors, which contribute to the chronic 
and relapsing nature of the illness. Treatment for opioid 
use disorder with methadone, a synthetic opioid ago-
nist, has been shown to be effective in reducing rates of 
relapse [3, 4]; however, there are a number of patients 
who continue to abuse opioids while in treatment, with 
little to no progress in their recovery.
The success of opioid agonist treatments is likely to 
be influenced by individual differences in gene profiles 
[5]. Evidence for the heritability of opioid use disorders 
has long been established [6–14], from which an inter-
est in the specific genetic variability of opioid use disor-
der and methadone maintenance treatment (MMT) has 
evolved [5, 15]. Existing genetic studies have explored 
the therapeutic response to MMT, with a focus on opi-
oid use relapse and methadone dosing. Opioid receptor 
genes, specifically OPRM1, and methadone metabolism 
genes, including ABCB1 and CYP450, are among the 
most commonly studied genes to date [16–22]. However, 
the association between methadone treatment response 
and other genes such as those involved in substance use 
behaviors and reward mechanisms remains unknown, 
despite evidence suggesting their contribution to opioid 
use disorder [23, 24].
The brain-derived neurotrophic factor (BDNF) gene 
encodes the neurotrophic protein, BDNF, which mod-
ulates neuron survival and neurotransmission [25]. 
Located on chromosome 11p13-15, BDNF has been 
identified as a strong candidate gene in multiple psy-
chiatric and substance use disorders [26–29], including 
opioid use disorder [30–32], as well as for certain addic-
tive behaviors such as drug seeking, impulsivity, polysub-
stance use, and cigarette smoking [33–35]. The BDNF 
196G>A single nucleotide polymorphism (SNP) rs6265, 
also known as Val66Met, is found in the pro-BDNF 
region of the gene and inhibits secretion of the BDNF 
protein. Val66Met has been linked with deficits in neu-
rotrophin and neurotransmitter release in specific areas 
that are responsible for behavior, learning, and memory 
[36, 37]. In the context of methadone treatment, BDNF 
has been explored in relation to BDNF plasma levels [30] 
and methadone dose [38], with only one study examin-
ing methadone treatment response to date [39]. In their 
study of 91 patients enrolled in an MMT program, de 
Cid and colleagues found that a haplotype block in the 
BDNF genomic region (GenBank accession number 
NC_000011; including 21 polymorphisms in a 63.8  kb 
region of coding sequence, and 3′ and 5′ untranslated 
regions) containing this specific SNP was more frequent 
in nonresponders compared to responders. However, the 
generalizability of these findings is limited by small sam-
ple size, large confidence intervals (CIs), and short period 
of urinalysis testing (previous four urine screens) [39].
Similarly, the dopamine receptor D2 (DRD2) gene 
plays a major role in opioid use disorders because of its 
involvement in the reward–dependence pathway [40]. 
The DRD2 gene is localized to chromosome 11q23 and is 
responsible for the synthesis of dopamine D2 receptors, 
which are involved in many signaling and neurotrans-
mission processes underlying addiction, including moti-
vation, pleasure, and reward. A reduction in dopamine 
receptor signaling has been linked to reward deficiency 
syndrome, whereby continuous use of opioids acts to 
compensate for this inhibited dopamine release or “low 
reward” state [41]. The dopaminergic system mediates 
withdrawal and drug-related learning [42] and is there-
fore an important candidate gene for studying opioid 
use and methadone treatment response. To date, most of 
the addiction literature involving DRD2 has focused on 
the Taq1A (rs1800497) polymorphism [43–46]. There 
is also widespread evidence for an effect of Taq1A on 
methadone dose, metabolism, and response, which is 
most often associated with poor outcomes [24, 40, 43, 
47, 48]. However, as the DRD2 gene is heavily involved 
in the activation of dopamine reward circuitry, it is likely 
that other SNPs that have not been investigated as exten-
sively as Taq1A are associated with methadone treatment 
outcomes. A promising target polymorphism, DRD2-
241A>G (rs1799978), is of particular interest, as it has 
shown preliminary evidence for an association with opi-
oid use disorder and methadone dose in a sample of 85 
German drug users admitted to an outpatient methadone 
treatment center [43].
Despite evidence for a strong association with addictive 
and reward behaviors, few studies of BDNF rs6265 and 
DRD2 rs1799978 in the context of opioid dependence 
and response to methadone treatment are available, and 
those are often limited by small samples or variation in 
the definitions of methadone treatment response. Based 
on existing literature, there is high potential for these 
SNPs to demonstrate an effect on methadone treatment 
response, which may have important implications for 
treatment prognosis. The current study aims to exam-
ine the genetic contribution to methadone treatment 
response (continued opioid use) in individuals with opi-
oid use disorder, with a specific focus on addiction-
related genes, BDNF and DRD2. We hypothesize that 
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carriers of the minor alleles of both rs6265 and rs1799978 
will be more likely to engage in continued illicit opioid 
use during methadone treatment, indicating poor treat-
ment response.
Methods
We have reported detailed methods of this study sample 
previously [49]. Data used in this study were collected 
as part of the GENetics of Opioid Addiction (GENOA) 
research program, in collaboration with Canadian Addic-
tion Treatment Centres (CATC; formerly known as 
Ontario Addiction Treatment Centres, or OATC) and 
the Population Genomics Program at McMaster Uni-
versity. This study is a cross-sectional analysis of men 
and women with a DSM-IV opioid dependence disor-
der, recruited consecutively from four outpatient meth-
adone clinics across Southern Ontario between June 
and December of 2011. This study was approved by the 
Hamilton Integrated Research Ethics Board (HIREB), 
and written informed consent was obtained from each 
participant.
Participants were included in the study if they were 
≥18  years of age, enrolled in a methadone treatment 
program at the CATC clinics, on a stabilized dose for the 
past 3  months, and able to provide consent and blood 
samples. We utilized the genetic information from 240 
participant blood samples from the GENOA study in this 
investigation, in addition to substance use and medical 
history obtained through structured clinical interviews.
Illicit opioid use (referring to the use of illegal opioids, 
such as heroin, or using prescription painkillers that 
were not prescribed for the given individual/condition) 
was detected by regular urine screens (weekly/biweekly) 
and measured as the percentage of positive urine screens 
per total number of urine screens available. Participants 
with <80 % negative opioid urine screens were classified 
as using illicit opioids during treatment, or as treatment 
nonresponders. We also collected information on demo-
graphics, methadone treatment duration, methadone 
dose, age of initial opioid use, and psychiatric history.
SNP selection and genotyping
We selected the BDNF and DRD2 genes on the basis of 
evidence supporting their involvement in opioid depend-
ence and addictive behavior. The rs6265 and rs1799978 
SNPs were the preferred choices for the purpose of this 
investigation because of their association with substance 
use and psychiatric disorders among various clinical pop-
ulations [33–35, 50–52]. We isolated DNA from whole 
blood and performed genotyping using the Applied Bio-
systems® ViiA™ 7 Real-Time PCR System (Life Technolo-
gies Corp., Carlsbad, CA, USA) with Applied Biosystems 
TaqMan Genotyping Master Mix (Life Technologies 
Corp.), as described previously [49]. The genotype call 
rates were 97.7 and 99.2 % for BDNF rs6265 and DRD2 
rs1799978, respectively.
Urine toxicology
All participants underwent qualitative and semi-quanti-
tative urine analysis weekly/biweekly using the iMDx™ 
Analyzer and Prep Assay (NOVX Systems Inc., Rich-
mond Hill, ON, Canada). The urine toxicology assays 
were implemented as part of the treatment model to 
monitor methadone adherence and to identify use of opi-
oids. The iMDx™ test can differentiate between natural 
and synthetic opioids, allowing for easier identification 
of specific opioid use. Urine samples were collected and 
assayed at the respective methadone clinic sites.
Statistical analysis
Sample demographics were summarized using descrip-
tive summary measures expressed as mean (standard 
deviation, SD) for continuous variables and number (per-
cent) for categorical variables. Genotype and allele fre-
quencies were computed and tested for Hardy–Weinberg 
equilibrium.
We performed univariate analysis on sample charac-
teristics to evaluate differences between responders and 
nonresponders. Student’s t test was used for mean differ-
ences, and Chi square was used for categorical variables. 
We chose to use the results from these comparisons and 
include significant variables as covariates in our logistic 
regression model. We performed multivariable logistic 
regression analysis, with opioid use as the binary depend-
ent variable and the two genetic variants, BDNF rs6265 
(A/A vs. A/G vs. G/G) and DRD2 rs1799978 (G/A vs. 
A/A), as independent categorical variables adjusting for 
age, sex, ethnicity, methadone dose (mg), and duration 
of treatment (months). We also adjusted for the total 
number of urine screens to eliminate any effect of more 
frequent urine sampling, suggesting problematic behav-
ior throughout treatment (change in outcome per opioid 
screen). We classified continued opioid use as having 
<80  % negative opioid urine screens (treatment nonre-
sponders). This classification was based on data from our 
current sample and from previous literature demonstrat-
ing that 30–80  % of opioid urine screens generally test 
negative throughout the course of methadone treatment 
[53–55]. Given the maximum value of this range, indi-
viduals with greater than 80 % negative screens (or alter-
natively, less than 20  % positive screens) are considered 
to be in good standing and, therefore, responding well 
to treatment. Given that 85 % of the participants were of 
self-reported European origin, we did not perform sub-
group analyses based on ethnicity due to the small sam-
ple size of other ethnic groups in our study; this ethnic 
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distribution is in keeping with our region population 
mix. In our regression, participants of European origin 
were compared to non-European origin, and men were 
compared to women.
Regression results, including model coefficients (odds 
ratio, OR), corresponding CIs, and associated p values are 
reported. The criterion for statistical significance was set at 
alpha = 0.05. There were no missing data in our analyses. 
We performed all statistics using STATA Version 12 (Stata-
Corp LP, College Station, USA). The study is reported in 
adherence with the Strengthening the Reporting of Obser-
vational Studies in Epidemiology statement [56].
We confirmed the statistical power of this investigation 
post hoc using Quanto Version 1.2.4 (Morrison & Gau-
derman 2009, California, USA), with treatment response 
(continued opioid use) as the outcome variable. Using an 
additive, gene-only, unmatched case–control (1:2) model, 
including 240 methadone patients and a two-sided test 
with a p = 0.05 level of significance, we had 85 % power 
to evaluate the effect of BDNF rs6265 (minor allele fre-
quency, MAF: 0.20) on methadone treatment response, 
with an OR of 1.5; and 70 % power to examine the effect 
of DRD2 rs1799978 (MAF: 0.05) on methadone treat-
ment response, with an OR of 1.8.
Results
Sample demographics
Of the initial 260 participants recruited from methadone 
clinics, 20 participants were excluded from the study 
(duplicate entries  =  5, buprenorphine treatment  =  3, 
missing blood sample or urine data = 8, being prescribed 
opioids for chronic pain condition =  4). Therefore, 240 
participants in total were included in the analysis (Fig. 1). 
The sample consisted of 144 (60.0 %) men and 96 (40.0 %) 
women, with a total mean age of 37.1 (SD = 10.4). Par-
ticipants of European ethnicity made up 85 % of the sam-
ple. A majority of participants (81.3 %; n = 195) reported 
having a family history of mental illness or addiction. 
Responders and nonresponders were comparable across 
the majority of factors. Additional details of sample char-
acteristics are shown in Table 1.
Genotypic profile
Genotype frequencies for rs6265 and rs1799978 are 
presented in Table  1. They did not deviate signifi-
cantly from Hardy–Weinberg equilibrium (p =  0.21 for 
rs6265; p  =  0.36 for rs1799978), and MAFs were con-
sistent with previous literature (0.20 for rs6265 and 0.05 
for rs1799978). Among our sample of 240 methadone 
patients, 36.3  % (n  =  87) had at least one rs6265 risk 
allele, and 11.3 % (n = 27) had at least one rs1799978 risk 
allele.
Genetic effect on opioid use during treatment
The continued use of opioids during methadone treat-
ment was an indication of treatment nonresponse 
and can be measured objectively across samples. This 
allowed us to examine whether there was a genetic com-
ponent to outcomes of methadone treatment. On aver-
age, 18.9 % (SD 24.1) of total urine screens throughout 
the duration of methadone treatment were positive 
for opioids in the total sample. Similar patterns were 
observed among genotype frequencies of responders and 
nonresponders (Table 1). Our logistic regression analysis 
showed that the minor alleles of BDNF rs6265 and DRD2 
rs1799978 were not associated with continued opioid 
use during methadone treatment, while adjusting for 
age, sex, ethnicity, age of initial opioid use, methadone 
dose, duration of treatment, and total number of opioid 
urine screens (rs6265: OR 1.37, 95  % CI 0.792, 2.371, 
p  =  0.260; rs1799978: OR 1.28, 95  % CI 0.511, 3.182, 
p = 0.603) (Table 2).
Discussion
Genetic association studies in addiction research aim 
to characterize genetic differences and variation in the 
processes that underly addiction and response to treat-
ment. Patients with opioid use disorder have significant 
interindividual variability in their clinical response to 
treatment, which may be attributed in part to genetic 
factors. Variation in addiction-related genes (such as 
BDNF and DRD2) due to polymorphisms in the genetic 
sequence may confer susceptibility to continued opi-
oid use while on methadone treatment for opioid use 
disorder.
Participants recruited between
June and December 2011
n = 260
Subjects assessed for 
inclusion/exclusion requirements
n = 255
Subjects excluded due to duplicate entry
n = 5
Subjects that failed to meet inclusion 
criteria and reasons for exclusion
n = 15
- On buprenorphine for opioid-agonist
therapy (n = 3)
- Using prescription opioids for chronic 
pain (n = 4)
- Missing blood sample or urine data  (n 
= 8)
Total participants eligible for study 
inclusion
N = 240
Fig. 1 Flow diagram for participants included in study. Number of 
participants included at each stage of the study process and reasons 
for participant exclusion
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Summary of findings
In this study, we explored the effect of BDNF rs6265 
and DRD2 rs1799978 polymorphisms on an important 
methadone treatment outcome, continued opioid use, 
which represents an objective measurement of response 
to treatment. In our sample of 240 methadone patients of 
primarily European origin, we were unable to confirm a 
role for these specific SNPs in continued opioid use dur-
ing treatment.
Our findings are in line with a study by de Cid and col-
leagues, the only other study to examine the influence 
of BDNF rs6265 in methadone treatment response [39]. 
They performed a haplotype analysis of 30 SNPs in the 
BDNF coding region, including rs6265, in a sample of 
91 Caucasian individuals receiving methadone treat-
ment for opioid use disorder. Grouping their sample 
Table 1 Characteristics of patients on methadone treatment for opioid use disorder
Frequency for DRD2 rs1799978 G/G genotype is 0 % in this sample; therefore, descriptive statistics are not available
BDNF brain-derived neurotrophic factor, DRD2 dopamine receptor D2, SD standard deviation, MMT methadone maintenance treatment
Characteristic Total (N = 240) Responders (n = 167) Nonresponders (n = 73) p value
Age in years; mean (SD) 37.1 (10.4) 37.1 (10.7) 36.9 (9.6) 0.868
Male; n (%) 144 (60.0) 105 (62.9) 39 (53.4) 0.169
Married/common law; n (%) 93 (38.8) 66 (39.5) 27 (37.0) 0.711
Employed; n (%) 72 (30.0) 53 (31.7) 19 (26.0) 0.375
Completed post-secondary education; n (%) 81 (33.8) 52 (31.1) 29 (39.7) 0.196
Ethnicity
 European; n (%) 203 (84.6) 139 (83.2) 64 (87.7) 0.381
 Native North/South American; n (%) 19 (7.9) 14 (8.4) 5 (6.8) 0.686
 Asian; n (%) 2 (0.8) 2 (1.2) 0 (0) 0.348
 Persian; n (%) 1 (0.4) 1 (0.6) 0 (0) 0.508
Age of initial opioid use in years; mean (SD) 23.1 (9.2) 22.3 (8.8) 25.0 (9.8) 0.037
Current cigarette smokers; n (%) 214 (89.2) 145 (86.8) 69 (94.5) 0.210
Number of cigarettes smoked/day; mean (SD) 18.0 (10.1) 18.6 (10.5) 16.6 (9.2) 0.158
Psychiatric comorbidity, self-reported; n (%) 116 (48.3) 81 (48.5) 35 (47.9) 0.937
Family psychiatric history; n (%) 195 (81.3) 133 (79.6) 62 (84.9) 0.334
Alcohol use disorder; n (%) 42 (17.5) 29 (17.4) 13 (17.8) 0.934
Methadone dose (mg); mean (SD) 89.5 (60.8) 97.5 (67.5) 71.2 (35.9) 0.002
Duration of MMT (months); mean (SD) 40.5 (42.6) 44.2 (44.1) 31.8 (37.8) 0.042
Total number of opioid urine screens; mean (SD) 65.7 (23.7) 64.9 (20.7) 67.5 (29.6) 0.278
Opioid use (% positive urine screens); mean (SD) 18.9 (24.1) 5.4 (5.6) 49.8 (21.4) <0.001
BDNF rs6265 genotype frequencies; n (%)
 G/G 153 (63.8) 110 (65.9) 43 (58.9) 0.302
 A/G 81 (33.8) 52 (31.1) 29 (39.7) 0.196
 A/A 6 (2.5) 5 (3.0) 1 (1.4) 0.458
DRD2 rs1799978 genotype frequencies; n (%)
 A/A 213 (88.8) 150 (89.8) 63 (86.3) 0.427
 A/G 27 (11.3) 17 (10.2) 10 (13.7) 0.427
Table 2 Summary of multivariable regression results
LR χ2 (7) = 20.23, Prob > χ2 = 0.0165, Psuedo R2 = 0.0728, Log 
likelihood = −128.822
BDNF brain-derived neurotrophic factor, DRD2 dopamine receptor D2, OR odds 
ratio, CI confidence interval
Continued opioid use OR 95 % CI p value
Age: year 1.00 0.966, 1.038 0.928
Sex: male 0.64 0.349, 1.178 0.152
Ethnicity: European 1.83 0.715, 4.697 0.207
Age of initial opioid use: year 1.02 0.986, 1.060 0.235
Methadone dose: milligram 0.99 0.983, 0.998 0.016
Duration on treatment: month 1.00 0.987, 1.005 0.364
Total number of opioid screens 1.01 0.997, 1.024 0.148
BDNF rs6265: allele (A) 1.37 0.792, 2.371 0.260
DRD2 rs1799978: allele (G) 1.28 0.511, 3.182 0.603
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into responders and nonresponders, they were unable to 
establish an effect of rs6265 on response to methadone 
treatment [39], but found that a haplotype block contain-
ing this specific SNP appeared more frequently in non-
responders compared with responders. However, the 
generalizability of these findings is limited by small sam-
ple size, large CIs, and short period of urinalysis testing 
(previous four urine screens, or approximately 1 month) 
[39]. With respect to other methadone outcomes, 
another study demonstrated no effect of rs6265 on meth-
adone dose in a sample of 227 former heroin-dependent 
individuals in methadone treatment [38].
The rs1799978 SNP of DRD2 has only been examined 
in association with opioid dependence or methadone 
dose in two single-SNP and haplotype analyses. In both 
studies (by Hung et  al. [40]; Doehring et  al. [43]), the 
minor allele of rs1799978 was more common in opioid 
users. However, Hung et al. [40] demonstrated that car-
riers of the minor llele also required higher methadone 
doses in their sample of 321 methadone patients, which 
was not a consistent finding in the study by Doehring 
and colleagues for a sample of 85 German drug users 
[43], thus suggesting a potential ancestral influence of 
rs1799978 on methadone dose.
Although methadone dose was a significant predictor 
of continued opioid use in our regression analysis, this 
was an expected finding given the available evidence on 
methadone dosing in treatment [16, 57]. We included 
this variable to ensure that any effect found between the 
SNPs and continued opioid use was not explained by the 
relationship between methadone dose and continued 
opioid use.
Implications
Contrary to what the current literature suggests, although 
there may be a potential role for both BDNF rs6265 and 
DRD2 rs1799978 in susceptibility to opioid use disorder, 
the present study shows that these variants do not appear 
to exert large effects on continued illicit opioid use dur-
ing treatment with methadone. Treatment response may, 
however, be influenced by the collective genetic risk con-
ferred through multiple SNPs across several different 
genes (a polygenic effect). It is also possible that the con-
tinued illicit use of opioids during methadone treatment 
may be a result of other clinically relevant factors (i.e., 
medical or psychiatric comorbidity, social circumstances, 
life stressors, etc.).
Future directions
Given that there is little conclusive evidence to support 
a genetic impact on methadone treatment, there is a 
need for well-designed, powerful, genome-wide asso-
ciation studies to identify specific SNPs that are relevant 
to methadone treatment response. Perhaps with this 
information, we will be able to simultaneously examine 
multiple candidate genes to understand the genetic com-
position of polygenic psychiatric disorders. Implement-
ing the use of a gene score to assess an individual’s genetic 
load may prove to be a promising approach to predicting 
and identifying those patients who require closer moni-
toring or alternate treatment strategies to overcome their 
continued opioid use.
Future research should focus on investigating these 
questions in larger samples and in various populations to 
ensure validity. Furthermore, a thorough examination of 
other nongenetic determinants of continued opioid use 
may prove useful for identifying problematic areas that 
require modifications in treatment delivery. Additionally, 
the genetic effects of withdrawal symptoms and adverse 
methadone events may be a promising area of study.
Strengths and limitations
To our knowledge, this is one of few studies to investi-
gate the potential for an allelic effect of BDNF rs6265 
and DRD2 rs1799978 on continued illicit opioid use 
among a large sample of methadone patients. These fac-
tors have not been thoroughly investigated in the context 
of methadone treatment response (as measured objec-
tively through urine toxicology screens), which highlights 
a novel direction of research in the treatment of opioid 
use disorder with opioid-agonist treatments. Through 
this analysis, we aim to stimulate further research into 
potential polygenic influences on methadone treatment 
outcomes, as well as to confirm our findings in a larger 
sample of methadone patients. The uniformity of our 
cohort, attributed to consistency in delivery of treatment 
and standard of care across CATC clinics, ensures repre-
sentativeness of the entire methadone patient population 
across Ontario, and likely throughout all of Canada. Our 
objective selection and definition of outcome measure-
ments—specifically, continued opioid use—is also a note-
able strength of this study.
Despite our negative findings, this study should be rep-
licated in a larger sample using multiple genes in order 
to confirm a lack of association between BDNF rs6265 
or DRD2 rs1799978 and methadone treatment response. 
Because the frequencies of the minor alleles were rela-
tively low in our sample, a larger sample size may be 
required to estimate with confidence the effect of these 
variants on continued illicit opioid use.
In summary, the present study has demonstrated a lack 
of association between the two genetic variants (BDNF 
rs6265 and DRD2 rs1799978) and MMT response, con-
trary to what previously had been believed about the role 
of these variants in psychiatric disorders and addictive 
behavior. Further research with larger samples is needed 
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to re-evaluate this question, as well as to investigate mul-
tiple genes simultaneously to assess polygenic effects on 
susceptibility to poor treatment response. Nevertheless, 
this study elucidates the potential for other nongenetic 
determinants that may contribute to continued opioid 
use during methadone treatment; it also brings atten-
tion to further questions regarding the role of genetics in 
addiction research.
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